Solutions
keyboard_arrow_downServices
keyboard_arrow_downSupport & Resources
keyboard_arrow_downCompany
keyboard_arrow_downContact
What We Do
You may know Randox as the sponsor of the Randox Grand National or as Team GB’s Official Diagnostic Health Partner. But for over 40 years, our focus has been advancing diagnostics to improve health worldwide while promoting proactive healthcare.
Innovation in Diagnostics
Backed by over £350m investment, our patented Biochip Technology allows multiple tests to be performed simultaneously, giving clinicians access to faster, more accurate insights. With around 70% of medical decisions based on lab results, we believe earlier, more accessible diagnostics are the key to saving lives and reducing pressure on healthcare systems.
The Future of Healthcare
With over 40 years of health testing experience and more than 21 million tests completed since 2023, we’re committed to helping people like you shape a healthier future. From comprehensive proactive health checks to a full range of home testing kits we’ve got you covered. With 30+ Randox Health clinics across the UK, Ireland and USA truly preventive healthcare is more accessible than ever before.
Established in 1982 Randox has been a world leader in in-vitro diagnostics for over 4 decades.
More than 5% of the world's population (over 400 million people) receive a diagnosis using Randox products every year.
Randox manufacture 15% of all worldwide cholesterol tests and 10% of all clinical chemistry tests.
RIQAS is the worlds largest EQA scheme with over 90,000 participants globally.
Randox is a major exporter with offices and distribution in over 145 countries worldwide.
We reinvest 25% of turnover in R&D and have more new tests in development than any other company.
Patented biochip technology the result of over £350 million investment is truly revolutionary.
We have over 3300 employees including 650 R&D scientists and engineers.
Randox responded quick to the COVID-19 pandemic developing an assay within weeks. Significant contributor to UK governments testing programme.
Unrivalled test menu spanning over 500 drugs and drug metabolites.
Over 150 patents across biochip technology, drugs of abuse and food diagnostic tests.
We supply our products to a range of diagnostic manufacturers and have more than 100,000 end user clients.
The Randox ethos of improving healthcare, which drove our Managing Director Dr Peter FitzGerald to start the company in the 1980s, continues today. Up to 25% of our turnover is reinvested in research and development to enable our scientists to work on the development of pioneering tests for a range of common illnesses such as cancer, cardiovascular disease and Alzheimer's disease.
We have also spent more than £220 million developing our patented Randox Biochip. This state-of-the-art biochip technology has revolutionised the diagnostics industry because it allows multiple tests to be carried out from a single, undivided patient sample on a single testing platform.